NSD1

Across TCGA pan-cancer cohorts, NSD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NSD1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NSD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NSD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where NSD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.862	0.478	.001	20	view →
PDAC	OS	Median	II,III,IV	0.559	0.207	.002	20	view →
UCEC	DFS	Tertile	III,IV	1.000	0.366	.016	16	view →
LSCC	DFS	Median	III,IV	1.000	0.589	.007	8	view →
HNSC	DFS	Median	IV	0.669	0.907	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NSD1–LUAD (OS)

Open the LUAD breakdown →